Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women

Journal of Clinical Pharmacology

Volumn 49, Issue 9, 2009, Pages 1037-1046

  Morton, Terri L ^a   Gattermeir, David J ^a   Petersen, Craig A ^b   Day, Wesley W ^b   Schumacher, Robert J ^a  

^a KV Pharmaceutical Company   (United States)

^b Menlo Park and VIVUS   (United States)

Author keywords

Estradiol; Evamist; Hormone replacement; Menopause; Pharmacokinetics; Transdermal

Indexed keywords

ESTRADIOL; ESTRONE; ESTRONE SULFATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG ERUPTION; FEMALE; HUMAN; HYPESTHESIA; MAXIMUM PLASMA CONCENTRATION; METABOLITE; NORMAL HUMAN; PARESTHESIA; PLASMA CONCENTRATION-TIME CURVE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AREA UNDER CURVE; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TIME FACTORS;

EID: 69549091638     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009339187     Document Type: Article

References (32)

1. Rapkin AJ Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol. 2007 ; 196: 97-106.
2. Gambacciani M., Ciaponi M., Cappagli B., et al. Effects of low-dose continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas. 2005 ; 50: 91-97.
3. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002 ; 77: 1207-1218.
4. Sikon A., Thacker HL Treatment options for menopausal hot flashes. Cleve Clin J Med. 2004 ; 71: 578-582.
5. Powers MS, Schenkel L., Darley PE, Good WR, Balestra JC, Place VA Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17?2-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol. 1985 ; 152: 1099-1106.
6. Harrison LI, Riedel DJ, Chang SF, et al. Comparative serum estradiol profiles from a new once-a-week transdermal estradiol patch and a twice-a-week transdermal estradiol patch. Ther Drug Monit. 1997 ; 19: 37-42.
7. Buch A., Shen L., Kelly S., et al. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara. Menopause. 1998 ; 5: 107-112.
8. Boyd RA, Zegarac EA, Eldon MA, Sedman AJ, Forgue ST Characterization of a 7 day 17?2-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women. Biopharm Drug Dispos. 1996 ; 17: 459-470.
9. Hossain M., Quebe-Fehling E., Sergejew T., et al. Dose proportionality study of four doses of an estradiol transdermal system, Estradot?«. Maturitas. 2003 ; 46: 173-185.
10. Balfour JA, Heel RC Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs. 1990 ; 40: 561-582.
11. Longcope C. Hormone dynamics at the menopause. Ann NY Acad Sci. 1990 ; 592: 21-30.
12. Lievertz RW Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol. 1987 ; 156: 1289-1293.
13. Pang SC, Greendale GA, Cedars MI, et al. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril. 1993 ; 59: 76-82.
14. Sarrel PM Ovarian hormones and the circulation. Maturitas. 1990 ; 12: 287-298.
15. Baker VL Alternatives to oral hormone replacement. Primary Care Mature Woman. 1994 ; 21: 271-297.
16. Ibarra de Palacios P., Schmidt G., Sergejew T., et al. Comparative study to evaluate skin irritation and adhesion of Estradot and Climera in healthy postmenopausal women. Climacteric. 2002 ; 5: 383-389.
17. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womenĝ€™s Health Initiative randomized controlled trial. JAMA. 2002 ; 288: 321-333.
18. Morgan TM, Oĝ€™Sullivan HMM, Reed BL, Finnin BC Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol. J Pharm Sci. 1998 ; 87: 1226-1228.
19. Buster JE, Koltun WD, Pascual MLG, Day WW, Peterson C. Low-dose estradiol spray to treat vasomotor symptoms, a randomized, controlled trial. Obstet Gynecol. 2008 ; 111: 1343-1351.
20. Draize JH Dermal and eye toxicity tests. In: Principles and Procedures for Evaluating the Toxicity of Household Substances. Washington, DC: National Academy of Sciences ; 1977.
21. Draize J., Woodard G., Calvery H. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944 ; 82: 377-390.
22. Smith BP, Vandenhende, FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000 ; 17: 1278-1283.
23. Simon JA, Bouchard C., Waldbaum A., et al. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2007 ; 109: 588-596.
24. Vivelle-Dot?« (estradiol transdermal system) [package insert]. Basel, Switzerland: Novartis Pharmaceuticals ; 2004.
25. Brennan JJ, Zhihong L., Whitman M., et al. Serum concentrations of 17?2-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women. Ther Drug Monit. 2001: 23: 134-138.
26. Setnikar I., Rovati LC, Santoro A., et al. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch. Arzneim-Forch. 1999 ; 49: 708-715.
27. Haas S., Walsh B., Evans S., et al. The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period. Obstet Gynecol. 1988 ; 71: 671-676.
28. Lippert TH, Seegar H., Mueck AO Estradiol metabolism during oral and transdermal estradiol replacement therapy in post-menopausal women. Horm Metab Res. 1998 ; 30: 598-600.
29. Samsioe G. Transdermal hormone therapy: gels and patches. Climacteric. 2004 ; 7: 347-356.
30. Evamist?« (transdermal estradiol spray) [package insert]. Bridgeton, MO: Ther-Rx Corporation ; 2007.
31. Estrogel?« 0.06% (estradiol gel) [package insert]. Marietta, GA: Unimed Pharmaceuticals ; 2004.
32. Estrasorb?« (estradiol topical emulsion) [package insert]. East Brunswick, NJ: Esprit Pharma ; 2005.